TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Result of General
Meeting
and
Total Voting
Rights
Alderley Park, UK - 7 March 2025: TheraCryf plc
(AIM: TCF), the clinical stage drug development company focussing
on oncology and neuropsychiatry, announces that
at the General Meeting held today at Mereside - No. 11
Lecture Theatre, Alderley Park, Alderley Edge, Macclesfield, SK10
4TG, all resolutions were duly passed.
Details of the proxy voting instructions lodged
prior to the General Meeting for each Resolution are shown on the
Company's website.
Total Voting
Rights
The 1,620,315,527 New Ordinary Shares to be
issued pursuant to the Fundraising are expected to be admitted to
trading on AIM at 8 a.m. on 11 March 2025. Following this Second
Admission, the total number of Ordinary Shares in issue will be
2,129,622,422, with no shares held in treasury. This is the figure
that may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Unless otherwise defined herein, terms used in
this announcement have the meaning given to them in the £4.25m
Placing & Subscription and Notice of GM announcement dated 19
February 2025.
Enquiries
|
TheraCryf plc
Dr Alastair Smith, Chair
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44
(0)1625 315 090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD & Joint
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
|
+44 (0)20 7220 0500
|
|
Turner Pope Investments (Joint Broker)
James Pope / Andy
Thacker
|
+44
(0)20 3657 0050
|
|
Vigo Consulting
Rozi Morris
|
+44
(0)20 7390 0231
theracryf@vigoconsulting.com
|
|
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to
generate compelling data sets to preclinical and/or clinical proof
of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla
SA, in neurodevelopmental disorders. The Company has sourced
know how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and the
University of Michigan.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is quoted on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com.
